September 5, 2017: Protembis announces successful first-in-human use of its ProtEmbo Cerebral Protection System in European trial
Protembis announced today the first clinical applications of its ProtEmbo Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo System is an intra-aortic filter device that deflects embolic material arising during TAVR away from the brain.
October 26, 2018: Protembis Successfully Closes $ 10 Million Series A Financing Round
Protembis announced today that it has raised a total of $ 10 million in an oversubscribed Series A financing round. The funding will enable the company to bring its product to market maturity.
July 25, 2017: Protembis initiates collaboration with German Accelerator Life Sciences
Protembis initiates the collaboration with the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), to facilitate its U.S. expansion and accelerate its clinical development plans.
April 24. 2015: Protembis wins state subsidy programme
Protembis wins state subsidy programme “KMU-innovativ” for innovative small and medium-sized enterprises granted by Germany's Federal Ministry of Education and Research.
July 28, 2015: Medical device company Protembis GmbH has closed its seed financing round
Led by Innovationsstarter Fonds Hamburg GmbH, Geratherm Medical AG and a group of angel investors, the financing will fund R&D and clinical trials of its novel cerebral protection device.
January 9, 2018: Protembis achieves ISO 13485:2016 Quality Management System Certification
Protembis announced today its successful certification in compliance with ISO 13485:2016. ISO 13485:2016 indicates that the Protembis Quality Management System complies with the stringent, international ISO standards for the design and development of medical devices. The certification was provided by BSI Group.
Come and meet Protembis